Abstract

Purpose: Studies on early recurrence in gastrointestinal neuroendocrine carcinoma (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) are lacking and risk factors related to early recurrence are not clear. We evaluated risk factors for early recurrence in such patients and developed a predictive scoring model.Methods: Patients undergoing curative surgery for GI-NEC or MANEC between January 2010 and January 2019 were included. Early recurrence was defined as recurrence within 12 months after surgery. Risk factors for early recurrence were identified using logistic regression.Results: Of the 80 included patients, 27 developed early recurrence and 53 had no early recurrence. Independent risk factors associated with early recurrence included tumor location in the midgut/hindgut [odds ratio (OR) = 5.077, 95% confidence interval (CI) 1.058–24.352, p = 0.042], alkaline phosphatase (ALP) >80 (OR = 5.331, 95% CI 1.557–18.258, p = 0.008), and lymph node ratio (LNR) >0.25 (OR = 6.578, 95% CI 1.971–21.951, p = 0.002). Risk scores were assigned to tumor location (foregut, 0; midgut/hindgut, 1), ALP (≤80, 0; >80, 1), and LNR (≤0.25, 0; >0.25, 1). Patients with a high risk (score 2–3) for early recurrence had significantly shorter disease-free survival and overall survival than those with low- (score 0) and intermediate risks (score 1) (both p < 0.001). The novel scoring model had superior predictive efficiency for early recurrence over TNM staging (area under the curve 0.795 vs. 0.614, p = 0.003).Conclusion: Tumor location, preoperative ALP, and LNR were independent factors associated with early recurrence after curative surgery for GI-NEC or MANEC. The risk scoring model developed based on these three factors shows superior predictive efficiency.

Highlights

  • Neuroendocrine neoplasms (NENs), formerly known as “carcinoids,” are highly heterogeneous neoplasms originating from sensory and secretory neuroendocrine cells [1]

  • The 2010 World Health Organization (WHO) classification of tumors of the digestive system categorizes NENs according to the degree of tumor cell differentiation: well or moderately differentiated neuroendocrine tumor (NET), poorly differentiated neuroendocrine neoplasms (PDNEN) including neuroendocrine carcinoma (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) [4]

  • Recurrence is closely related to poor prognosis; early screening of GI-PDNEN patients who are at high risk of early recurrence is essential for their improved prognosis

Read more

Summary

Introduction

Neuroendocrine neoplasms (NENs), formerly known as “carcinoids,” are highly heterogeneous neoplasms originating from sensory and secretory neuroendocrine cells [1]. The 2010 World Health Organization (WHO) classification of tumors of the digestive system categorizes NENs according to the degree of tumor cell differentiation: well or moderately differentiated neuroendocrine tumor (NET), poorly differentiated neuroendocrine neoplasms (PDNEN) including neuroendocrine carcinoma (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) [4]. Adjuvant systemic chemotherapy is often required for patients with a high degree of malignancy. Previous studies have reported that the 1-year progression-free survival of GIPDNEN patients varies from 52 to 58%, indicating that a considerable number of patients will develop early recurrence within 12 months after surgery, despite treatment initiation with various adjuvant chemotherapy regimens [6,7,8]. Recurrence is closely related to poor prognosis; early screening of GI-PDNEN patients who are at high risk of early recurrence is essential for their improved prognosis. Far, the risk factors associated with early recurrence of GI-PDNEN are not clearly analyzed

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call